Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Diabetes Research and Clinical Practice

Volumn 110, Issue 3, 2015, Pages e27-e30

  Kim, Sun Hwa ^a   Kim, Sin Gon ^a   Kim, Doo Man ^b   Woo, Jeong Taek ^c   Jang, Hak Chul ^d   Chung, Choon Hee ^e   Ko, Kyung Soo ^f   Park, Jeong Hyun ^f   Park, Yong Soo ^g   Kim, Sang Jin ^h   Choi, Dong Seop ^a  

^a College of Medicine   (South Korea)

^b Hallym University   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e Wonju Severance Christian Hospital   (South Korea)

^f Inje University   (South Korea)

^g Hanyang University Guri Hospital   (South Korea)

^h Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Clinical trial; Lobeglitazone; Randomised trial; Thiazolidinediones

Indexed keywords

HEMOGLOBIN A1C; LIPID; LOBEGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PYRIMIDINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN; AGED; ANALYSIS; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE BLOOD LEVEL; MALE; MIDDLE AGED;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINES; THIAZOLIDINEDIONES;

EID: 84955202578     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.09.009     Document Type: Article

References (10)

1. Yki-Jarvinen H. Thiazolidinediones. NEJM 2004, 351:1106-1118.
2. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. NEJM 2006, 355:2427-2443.
3. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabet Care 2000, 23:1605-1611.
4. Charbonnel B.H., Matthews D.R., Schernthaner G., Hanefeld M., Brunetti P. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005, 22:399-405.
5. Hanefeld M., Brunetti P., Schernthaner G.H., Matthews D.R., Charbonnel B.H. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabet Care 2004, 27:141-147.
6. van Wijk J.P., de Koning E.J., Martens E.P., Rabelink T.J. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003, 23:1744-1749.
7. Eldor R., DeFronzo R.A., Abdul-Ghani M. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabet Care 2013, 36(Suppl. 2):S162-S174.
8. Hampp C., Borders-Hemphill V., Moeny D.G., Wysowski D.K. Use of antidiabetic drugs in the U.S., 2003-2012. Diabet Care 2014, 37:1367-1374.
9. Kim S.G., Kim D.M., Woo J.T., Jang H.C., Chung C.H., Ko K.S., et al. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLOS ONE 2014, 9:e92843.
10. Jin S.M., Park C.Y., Cho Y.M., Ku B.J., Ahn C.W., Cha B.S., et al. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. Diabet Obes Metab 2015, 17:599-602.